| Elaprase 2 mg/ml concentrate for solution for infusion EU/1/06/365/1-3 |
Idursulfase |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Equasym XL 10 mg modified-release capsules, hard PA23211/001/001 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Equasym XL 20 mg modified-release capsules, hard PA23211/001/002 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Equasym XL 30 mg modified-release capsules, hard PA23211/001/003 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Equasym XL 40 mg modified-release capsules, hard PA23211/001/004 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Equasym XL 50 mg modified-release capsules, hard PA23211/001/005 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Equasym XL 60 mg modified-release capsules, hard PA23211/001/006 |
Methylphenidate hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Firazyr 30 mg solution for injection in pre-filled syringe EU/1/08/461/001-002 |
Icatibant |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Foznol 1000 mg Chewable Tablets PA23211/002/004 |
Lanthanum |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Foznol 1000 mg Oral Powder PA23211/002/006 |
Lanthanum carbonate hydrate |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Foznol 250 mg Chewable Tablets PA23211/002/001 |
Lanthanum carbonate hydrate |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Foznol 500 mg Chewable Tablets PA23211/002/002 |
Lanthanum |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Foznol 750 mg Chewable Tablets PA23211/002/003 |
Lanthanum |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Foznol 750 mg Oral Powder PA23211/002/005 |
Lanthanum carbonate hydrate |
Takeda Pharmaceuticals International AG Ireland Branch |
Not marketed |
| Intuniv 1 mg prolonged-release tablets EU/1/15/1040/001-002 |
GUANFACINE HYDROCHLORIDE |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Intuniv 2 mg prolonged-release tablets EU/1/15/1040/003-005 |
GUANFACINE HYDROCHLORIDE |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Intuniv 3 mg prolonged-release tablets EU/1/15/1040/006-007 |
GUANFACINE HYDROCHLORIDE |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Intuniv 4 mg prolonged-release tablets EU/1/15/1040/008-009 |
GUANFACINE HYDROCHLORIDE |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| LIVTENCITY 200 mg film-coated tablets EU/1/22/1672/001-002 |
Maribavir |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Mezavant XL 1200 mg gastro-resistant, prolonged release tablets PA23211/004/001 |
Mesalazine |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Plenadren 20 mg modified-release tablets EU/1/11/715/002 |
Hydrocortisone |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Plenadren 5 mg modified-release tablets EU/1/11/715/001 |
Hydrocortisone |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Qdenga powder and solvent for solution for injection EU/1/22/1699/001 |
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Qdenga powder and solvent for solution for injection EU/1/22/1699/002 |
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Qdenga powder and solvent for solution for injection EU/1/22/1699/003 |
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Qdenga powder and solvent for solution for injection EU/1/22/1699/004 |
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Replagal 1 mg/ml concentrate for solution for infusion EU/1/01/189/001 |
Agalsidase alfa |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Resolor 1 mg film-coated tablets EU/1/09/581/001 |
Prucalopride Succinate |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Resolor 2 mg film-coated tablets EU/1/09/581/002 |
Prucalopride Succinate |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Revestive 1.25 mg powder and solvent for solution for injection EU/1/12/787/003 |
Teduglutide |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Revestive 5 mg powder and solvent for solution for injection EU/1/12/787/001 |
Teduglutide |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| TAKHZYRO 150 mg solution for injection in pre-filled syringe EU/1/18/1340/007-009 |
LANADELUMAB |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| TAKHZYRO 300 mg solution for injection EU/1/18/1340/001 |
LANADELUMAB |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Tyvense 20 mg capsules, hard PA23211/005/001 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Tyvense 30 mg capsules, hard PA23211/005/002 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Tyvense 40 mg capsules, hard PA23211/005/003 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Tyvense 50 mg capsules, hard PA23211/005/004 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Tyvense 60 mg capsules, hard PA23211/005/005 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Tyvense 70 mg capsules, hard PA23211/005/006 |
Lisdexamfetamine dimesylate |
Takeda Pharmaceuticals International AG Ireland Branch |
Marketed |
| Xagrid 0.5 mg hard capsules EU/1/04/295/001 |
Anagrelide hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
— |